Determinants of Response of HER2+ Gastric Cancer vs Gastroesophageal Adenocarcinoma to Pembrolizumab post Trastuzumab


Background

Margetuximab is a novel antibody-drug conjugate (ADC) targeting HER2. Here, we compared margetuximab efficacy and safety between HER2+ gastric cancer and HER2+ adenocarcinoma.

Methods

Two randomized studies were conducted: MARGO (NCT02698284), a multicenter, open-label Phase II study of margetuximab in HER2+/HER2-negative gastric cancer, and MAHER-023 (NCT04181585), a Phase II study in HER2+ advanced gastroesophageal adenocarcinoma.

Conclusions

Margetuximab demonstrated a promising overall therapy and manageable toxicity for both HER2+ gastric cancer and HER2+ adenocarcinoma.